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Introduction
The occurrence of feline leishmaniosis (FeL) has 
increased worldwide, revealing a possible role of 
cats in leishmaniosis epidemiology. Better accuracy of 
laboratory techniques has improved the diagnosis of 
this disease, and changes in ecosystems over the last 
few years associated with the use of repellents on dogs 
might play a role in sandflies’ altered feeding patterns 
in urban areas, leading to infections in other mamma-
lian hosts.1–3
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Abstract
Case summary This work describes the diagnosis and successful treatment of a 2-year-old domestic cat infected 
with Leishmania species and presenting fever, and ulcerative and nodular skin lesions after being treated for 
pyodermatitis for 1 year without clinical improvement. After anamnesis the cat was submitted to a complete clinical 
examination. Blood was collected for determination of haematological and biochemical parameters, detection 
of feline leukaemia virus (FeLV), feline immunodeficiency virus (FIV), feline coronavirus (FCoV) and Leishmania 
amastigotes. Fine-needle aspiration puncture from the skin nodules was also performed. After definitive diagnosis 
the animal was treated and followed up over a 2 year period. The animal tested negative for FIV-specific antibodies, 
FeLV antigen and feline coronavirus RNA. Leishmania amastigotes in the skin nodules were confirmed by cytology 
and molecular diagnosis. Treatment was initiated with allopurinol, resulting in a slight clinical improvement. Thus, 
N-methyl-glucamine antimoniate was added and administered for 30 days, with complete closure of the ulcerative 
lesions in the hindlimbs requiring a surgical approach. Close monitoring of the patient in the following 24 months 
indicated that combined therapy was safe and clinical cure was achieved without further relapses or side effects.
Relevance and novel information Considering the increasing number of feline leishmaniosis cases and the 
inconsistent results of most therapeutic protocols described in the literature, the use of new approaches, especially 
in refractory cases, is essential. Although the use of allopurinol and N-methyl-glucamine antimoniate is off-label in 
cats, in this case the combination treatment was followed by an extensive analytical monitoring, supporting their 
safety and effectiveness.
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Worldwide epidemiological surveys of Leishmania 
species causing feline asymptomatic infection and FeL 
have been reported.4,5 In Europe, Spain had the first 
described FeL case in 1932.6 Some authors claim that low 
prevalence of FeL in endemic areas may be related to a 
natural resistance to the parasite in cats.7 Moreover, the 
number of clinical cases may be underestimated, leading 
to few reports and lack of information by clinicians and 
owners. Although Portugal is an endemic country for 
canine leishmaniosis caused by Leishmania infantum, 
there are few published clinical reports of FeL, with the 
first description of it in 1994 in Sesimbra, followed by 
others in Porto and Lisbon.8–10
Despite occasional reports of ocular and visceral dis-
ease, dermatological, mucocutaneous/mucosal presen-
tations and lymph node enlargement are the most 
frequent clinical features.11–14 Clinical suspicion is based 
on history, clinical signs and clinicopathological abnor-
malities. Diagnosis is confirmed with parasitological 
and serological methods.15
A long-term administration of allopurinol (10–20 
mg/kg q12h or q24h) is the most recommended treat-
ment protocol for FeL,10,11,15 however, similarly to dogs, 
recurrence can occur if the infection is not cleared. Some 
authors have reported a good clinical response using 
N-methyl-glucamine antimoniate monotherapy (5–100 
mg/kg or 375 mg/cat q24h SC or IM under different 
protocols).8,15
This study aims to describe the treatment of a recur-
ring clinical case of FeL in a cat receiving combined ther-
apy (allopurinol and N-methyl-glucamine antimoniate).
Case description
A 2-year-old domestic European neutered male cat was 
referred to the Veterinary Teaching Hospital of the 
Faculty of Veterinary Medicine, University of Lisbon, 
with multiple nodular skin lesions (Figure 1), ulcerative 
dermatitis involving the four limbs (Figure 2) and fever. 
The cat was referred 1 year after the onset of skin lesions 
and was previously treated for a presumptive pyoder-
matitis with prednisolone (1 mg/kg PO q12h for 12 
days) and amoxicillin/clavulanic acid (20 mg/kg PO 
q12h for 6 days), followed by doxycycline (5 mg/kg PO 
q12h for 8 days), and showed no clinical improvement.
The cat was not vaccinated, but had been regularly 
protected against ectoparasites with fipronil and imida-
cloprid. At first admission, mild fever (39.5ºC) and der-
matological lesions on the head and limbs were the only 
abnormalities on physical examination. About 20–25 
skin nodules measuring 2–10 mm in diameter were dis-
tributed on the outer pinnal surfaces (Figure 1a) and 
orbital regions (Figure 1b). Most of them were observed 
on the pinnae, where they gathered with coalescing pat-
terns. Differential diagnosis was pyodermatitis, allergic 
reaction, autoimmune disease, neoplastic disease or 
Figure 1 Skin nodules measuring 2–10 mm in diameter were 
distributed on the (a) outer pinnal surfaces and (b) orbital 
regions. Most of them were observed on the right pinna, 
where they gathered with coalescing patterns
Figure 2 Single spots (between 20 and 50 mm in diameter) of ulcerative dermatitis that had raised margins affecting the  
(a) antebrachial and (b) hock regions after disinfection of lesions
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leishmaniosis. Single spots (20–50 mm in diameter) of 
ulcerative dermatitis, which had raised margins, affected 
the antebrachial (Figure 2a) and hock (Figure 2b) regions.
A complete blood count and biochemical profile were 
used to evaluate the clinical status of the cat before treatment, 
after treatment and at all follow-up examinations. Urinalysis 
and urinary protein: creatinine ratio were evaluated 
6 months after treatment. Haematological and biochemical 
values were within the reference intervals. Serum protein 
electrophoresis showed an albumin: globulin ratio, but a 
slight hypergammaglobulinaemia was evident (Table 1).
The patient was tested for FIV-specific anti- 
bodies, FeLV antigens by ELISA (ViraCHEK/FIV and 
ViraCHEK/FeLV, respectively; Synbiotics) and immuno-
flourescence antibody test (IFAT) using an adaptation 
of Leishmania Spot IFI kit (bioMérieux) with a fluores-
cently labelled anticat IgG conjugate (anticat IgG 
MegaCor; MegaCor Diagnostik), which was used 
to quantify anti-Leishmania antibodies (cut-off 1:40). 
Previous studies, including more than 100 cats, validated 
this latter test in inter-laboratory assays using known 
positive and negative sera, with results as expected. 
Repeatability and reproducibility were also assessed 
(unpublished results). The cat tested negatively for FIV 
antibodies and FeLV antigens, but was positive for anti-
Leishmania antibodies, with a titre ⩾1:1280 (Table 1).
Table 1 Haematological, biochemical and serological results obtained before, during and after treatment
Day 0 Day 45 Month 6 Month 12 Month 18 Month 24 Reference 
intervals
Haemogram
 Leukocytes (×10³/µl) 13.3 15.0 10.0 NA NA 15.6 5.5–19.5
 Erythrocytes (×106/µl) 6.6 9.2 10.2 NA NA 9.5 5.0–10.0
 Platelets (×10³/µl) 185 327 129 NA NA 223 300–700
 Haemoglobin (g/dl) 9 12 14 NA NA 13 8–15
 PCV (%) 29 40 40 NA NA 43 24–45
 Non-segmented neutrophils (/µl) 0 0 0 NA NA 0 0–300
 Segmented neutrophils (/µl) 9.520 11,000 6.468 NA NA 7.000 2.500–12.500
 Lymphocytes (/µl) 2.856 3000 2.980 NA NA 2.800 1.500–7.000
 Monocytes (/µl) 0.5 0.3 0.1 NA NA 4.7 0–850.0
 Eosinophils (/µl) 0.680 0.600 0.390 NA NA 0 0–1.500
 Basophils (/µl) 0 0 0 NA NA 0 Rare
Biochemical parameters
 Urea (mg/dl) 48.7 52.9 50.0 NA 52.3 59.9 0–82.0
 Creatinine (mg/dl) 0.73 0.97 1.07 NA 1.23 1.25 0.70– 2.20
 ALT (U/l) 37 37 35 NA 45 37 10–130
 AST (U/l) NA NA NA NA 28 28 8–35
 Alkaline phosphatase (U/l) NA NA 43 NA 21 32 20–220
 Calcium (mmol/l) NA NA NA NA 9.52 8.92 9.40–11.20
 Total bilirubin (mg/dl) NA NA NA NA 0.06 0.05 0.08–0.30
 Potassium (mmol/l) NA NA NA NA 4.4 4.8 3.5–5.2
 Chloride (mmol/l) NA NA NA NA 123 137 108–128
 Sodium (mmol/l) NA NA NA NA 156 156 143–153
 Biliary acids (µmol/l) NA NA NA NA 3.68 3.53 1–20.00
 Inorganic phosphorus (mmol/l) NA NA NA NA 4.4 4.8 2.4–6.0
 Urinary protein: creatinine ratio (%) NA NA 0.04 NA NA NA <0.50
Serum protein electrophoresis
 Total protein (g/dl) 6.9 7.1 6.8 NA 7.2 NA 5.7–7.9
 Albumin (g/dl) 2.6 2.7 3.1 NA 3.2 NA 2.1–4.0
 Alpha 1 (g/dl) 0.4 0.1 0.1 NA 0.1 NA 0.2–1.1
 Alpha 2 (g/dl) 1.1 1.4 1.6 NA 1.7 NA 0.4–0.9
 Beta (g/dl) 0.4 1.1 0.9 NA 1.1 NA 0.9–1.9
 Gama (g/dl) 2.4 1.9 1.1 NA 1.1 NA 1.3–2.2
 Albumin: globulin ratio (%) 0.60 0.60 0.90 NA 0.80 NA 0.45–1.30
Antibody titre (IFAT)
 Anti-Leishmania antibodies ⩾1:1280 1:320 1:80 1:80 1:40 1:40  
PCV = packed cell volume; ALT = alanine aminotransferase; AST = aspartate aminotransferase; NA = not available
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Fine-needle aspiration puncture from the ear skin 
nodules was performed. Smears were stained with 
Giemsa (Merck) and examined under an optical micro-
scope (Olympus BX51). The aspirate was also used for 
further molecular and parasitological analysis. The 
smears revealed Leishmania amastigotes (Figure 3), and 
absence of bacteria/neutrophilic infiltration or charac-
teristic cells of autoimmune diseases.
DNA extraction from EDTA blood samples, skin 
nodules and lymph node aspirates was carried out with 
a DNeasy Blood & Tissue kit (Qiagen). Detection of 
feline coronavirus from plasma was performed by 
reverse transcription quantitative PCR (RT-qPCR),16 
targeting the 3′ end of the virus genome. Additionally, 
qPCR using L infantum-specific Taqman probes target-
ing the kinetoplast minicircle DNA (kDNA) was also 
performed to determine the initial and follow-up para-
sitic load.17
RT-qPCR was negative for coronavirus, while qPCR 
of skin nodules and blood samples were positive for 
L infantum kDNA, showing a parasitic load of 1700 and 
0.1 parasites per 50 ng DNA, respectively (Table 2).
Nodular and lymph node aspirates were inoculated 
in Schneider’s Insect Medium (Sigma-Aldrich) supple-
mented with 0.6% (w/v) of CaCL2, 5 mM Hepes, 10% 
fetal bovine serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin.18 Cultures were maintained at 24ºC in a 
refrigerated incubator (Lovibond) and observed by opti-
cal microscopy after 8 days of incubation. Viable pro-
mastigotes were observed.
The cat was treated orally with 10 mg/kg allopuri-
nol q12h and a three-layered bandage was applied to 
the four limbs. Medical follow-up was performed 
every 2 days during the first fortnight. After 15 days of 
treatment with allopurinol only a slight clinical 
improvement was noted. Fever persisted and skin 
ulcers seemed equally profound. Therefore, a com-
bined therapeutic protocol not yet approved for cats 
was suggested to the owner. N-methyl-glucamine anti-
moniate administration is off-label in cats, with only a 
few published cases of FeL treated with this drug. 
After owner consent was obtained, treatment was rein-
forced with 50 mg/kg N-methyl-glucamine antimoni-
ate (Glucantime; Merial) q24h SC for 30 consecutive 
days. This study was conducted in the framework of 
FCT Project PTDC/CVT/118566/2010, with the agree-
ment of the Ethics Committee and Animal Welfare of 
the Faculty of Veterinary Medicine, University of 
Lisbon.
During and after treatment there were no abnormali-
ties reported by the owner. The cat maintained a normal 
physical condition19 and examination apart from the 
skin lesions.
Total remission of skin nodules on the head, as well 
as the foreleg ulcers, was achieved (Figure 4), with 
body temperature being normalised on day 45. 
Complete closure of the hindlimb ulcerative lesions did 
not occur owing to an extreme tension in those regions, 
which required surgery (Figure 5). One hour prior to 
surgery, the cat received a therapeutic protocol of 
Ringer’s lactate fluid therapy, amoxicillin with clavu-
lanic acid (8.75 mg/kg IM), buprenorphine (0.02 mg/
kg IM) and methylprednisolone succinate (1 mg/kg 
IM). Propofol (4 mg/kg IV) was used for the induction 
of anaesthesia followed by isoflurane for its mainte-
nance. Debridement and excision of the wound edges 
were performed and a horizontal mattress suture was 
used for closure. The excised edges of the defect were 
immersed in a 10% formalin solution to allow for histo-
pathological study.
The cat was medicated with antibiotic (amoxicillin/
clavulanic acid, 12.5 mg/kg PO q12h for 10 days) and a 
non-steroidal anti-inflammatory (tolfenamic acid 4 mg/
kg PO q 24h for 4 days), and was assessed 48 h after sur-
gery in order to evaluate the regions operated on; stitches 
were removed on days 6 and 12. As an integral part of 
Figure 3 Fine-needle aspiration smear of a skin nodule 
showing many extracellular (small arrows) and intracellular 
Leishmania amastigotes in the cytoplasm of macrophages 
(large arrows). Giemsa stain, scale bar = 20 µm
Table 2 Leishmania infantum parasitic load detected by 
quantitative PCR before, during and after treatment
Parasitic load (number of parasites/50 ng total DNA)
 Day 0 Day 30 Day 45 Month 18
Skin nodules 1700 10 NA NA
Blood 0.10 0.05 0.05 0
Lymph node NA 100.0 0.1 0
NA = not available
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the healing process, the cat was maintained for 2 weeks 
with Robert-Jones bandages. The complete healing of 
hindlimb lesions was achieved 1 month after surgery 
(Figure 6).
Histological examination of the removed tissues 
showed a granulomatous-like inflammatory response 
with some foci of lymphocytes, activated plasmacytes 
and occasional intracellular amastigote forms of 
Leishmania species in macrophages.
The slight hypergammaglobulinaemia observed at 
admission returned to normal values. No further clinical 
or laboratory changes were detected 6, 18 and 24 months 
after the end of treatment (Table 1). Allopurinol was 
stopped when antibody titres decreased to 1:40 (18 
months). At month 24, the antibody level remained 
unchanged.
Parasitic load decreased in both blood and skin nod-
ules after 15 days of combined treatment. The lymph 
node parasitic load showed a pronounced decrease after 
day 30 (Table 2).
Discussion
FeL is rarely reported in various parts of the world.4,20,21 
In Europe, a total of 46 clinical cases have been published 
between 1989 and 2014, namely in Italy, France, Spain 
and Switzerland, with regards to cats imported from 
Spain.4,20,22–24 In Portugal, although the first clinical case 
was reported in the 1990s,8 only in recent years have epi-
demiological studies been conducted to better under-
stand the role of cats in the biological cycle of Leishmania 
species. In the metropolitan region of Lisbon, although 
the detection of anti-Leishmania antibody titres points to 
Figure 4 Cat 18 months after treatment with allopurinol and N-methyl-glucamine antimoniate (Glucantime; Merial), illustrating 
the absence of skin nodules on the ears and head
Figure 5 Intraoperative images showing the excision of the defect edges in the (a) right and (b) left hindlimb
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a low prevalence or, at least, low cat–parasite contact 
(1.3%), the detection of Leishmania DNA indicates high 
levels of infection in stray (30.4%) and domestic cats 
(20.3%). Even so, most of the animals are 
asymptomatic.3
This disease is seldom considered during the differen-
tial diagnosis in cats, as in the present clinical case, where 
the animal had been previously treated for other dis-
eases for 1 year.
Dermatological findings in FeL usually include ery-
thema, alopecia, papules, nodules, ulcers or crusts, with 
the head being the most affected region, but other body 
parts may also be affected.17,25,26 In the present clinical 
case, as the ulcers in the hindlimbs were severely con-
taminated at first examination, it was not possible to 
determine whether the fever was a systemic sign of 
FeL or a consequence of secondary bacterial infection. 
Concerning the available therapeutics for FeL, this cat 
was first treated with allopurinol, which was insufficient 
despite its use being common in the treatment of canine 
leishmaniosis. Even though the use of allopurinol is off-
label in both dogs and cats, there is a more extensive 
clinical experience of efficacy and safety in dogs. Under 
the scope of ‘cascade’ a combined therapeutic not yet 
approved for cats was suggested to the owner.
Initially, this cat showed very high antibody titres by 
IFAT as seen in other reported cases of FeL.12,13,23 After 2 
weeks of the combined protocol the decrease in antibody 
titre and parasitic load was evident. Similarly to canine 
leishmaniosis, there was a gradual decline in antibody 
titre and it took around 18 months to attain the lowest 
titre. Clinical remission was accomplished together with 
surgical recovery in less than 2 months. Furthermore, 
this therapeutic protocol seemed to be safe for the cat as 
no analytical change or side effect was observed.
By 24 months of follow-up, no relapses had occurred. 
Regarding the albumin levels, although within the refer-
ence interval, the increase noted, associated with the 
decrease in gamma(γ)-globulin values, kept the total 
protein concentration within the reference interval, 
which is in agreement with the remission of clinical 
signs.
Cats may live for years with a slowly progressing 
chronic disease, even without a specific anti-Leishmania 
treatment.4,5,15 However, in this case, the severity of 
cutaneous lesions was the clinician’s main concern 
leading her to search for another therapeutic protocol 
when monotherapy with allopurinol proved to be 
insufficient.
Although full clinical recovery was achieved, it is 
possible that a much reduced number of viable parasites 
may have persisted (mainly in the lymph nodes) after 
the end of the treatment. However, as it is not possible to 
guarantee total elimination or its dispersion to the skin, 
parasite transmission should be kept in mind. These 
facts highlight the need for new topical insecticides aim-
ing to prevent sandfly bites in cats, as all insecticide 
products currently registered against sandflies contain 
permethrin, which is extremely toxic to cats.
Conclusions
The present work describes a successful case of FeL treat-
ment in a young cat, negative for FIV antibodies and 
FeLV antigenaemia, after a 15 day refractory period 
using allopurinol monotherapy. To the best of our knowl-
edge, this is the first report of a combined therapy, using 
allopurinol and N-methyl-glucamine antimoniate with 
no relapses or adverse effects, resulting in a possible new 
treatment for use in FeL refractory cases.
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Figure 6 Hindlimbs 4 weeks after surgery
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